A batch of blood pressure pills meant to help control a dangerous condition instead failed the basic lab test proving it actually works the way it should.
Quick Take
- Inventia Healthcare recalled 13,567 bottles of 25-mg chlorthalidone tablets after they failed dissolution testing.
- The Food and Drug Administration (FDA) classified the recall as Class II, meaning a remote chance of serious harm but possible temporary effects.
- The affected lot, batch RISA24002, was distributed nationwide and expires April 2027.
- This marks the second dissolution-related recall from the same manufacturer in three months, following a June recall of 11,460 bottles.
What The Recall Actually Covers
The FDA’s enforcement record lists recall number D-0610-2026 for chlorthalidone tablets that failed what regulators call dissolution specifications. That test checks whether a pill breaks down properly in the body so the drug can work as intended. The agency’s record identifies the affected product: 25-mg chlorthalidone tablets sold in 100-count bottles under National Drug Code 64980-599-01.
The specific batch is RISA24002, with an expiration date of April 2027. Manufacturer Inventia Healthcare Limited made the tablets, and reporting confirms the bottles reached pharmacies nationwide, not just one region or state. That nationwide reach is why the recall quickly caught public attention once regulators flagged it.
Chlorthalidone is a common generic drug doctors prescribe to lower blood pressure and reduce fluid buildup. Patients rely on it daily, often as part of a long-term treatment plan. When a quality test fails on a drug this widely used, the scale of the problem multiplies fast simply because so many people depend on consistent dosing to keep their condition under control.
How Regulators Classified The Risk
Inventia Healthcare voluntarily pulled the batch from the market on September 3, 2026. The FDA followed up two weeks later and officially classified the action as a Class II recall on September 17. That classification matters because it tells the public how serious regulators believe the risk actually is.
A Class II recall means the FDA sees a remote chance of serious harm, but it does not rule out temporary or reversible health effects. In plain terms, a patient taking an affected pill might not get the full blood-pressure-lowering effect they expect. Still, the agency has not tied this batch to confirmed injuries or hospitalizations in the available record. Patients are still advised to speak with a pharmacist or doctor rather than stop the medication on their own, since untreated high blood pressure carries its own serious risks.
A Pattern Worth Watching From The Same Manufacturer
This is not Inventia’s first dissolution problem this year. In June 2026, the company recalled 11,460 bottles covering two other batches, RISA24001 and RISB24002, for the identical reason: failed dissolution specifications. Two recalls tied to the same quality defect within a few months raise fair questions about whether the company’s manufacturing fixes actually solved the underlying problem.
Dissolution failures are not rare in the pharmaceutical industry. The FDA’s own quality report found dissolution problems accounted for 36 percent of failed-specification recalls industry-wide in fiscal year 2024, second only to impurity issues. That context shows this type of failure is a recognized, if serious, manufacturing risk across generic drug makers, not an isolated event unique to one company or one drug.
Why Generic Drug Oversight Deserves Scrutiny
Inventia Healthcare operates out of India, while its tablets were sold to American patients nationwide. That overseas-to-domestic pipeline is common in the generic drug industry. Still, it also means American consumers are trusting a manufacturing and testing process that happens thousands of miles from where the pills are swallowed. A repeat failure at the same facility is exactly the kind of track record that should prompt closer FDA inspection, not just another recall notice.
Patients currently taking chlorthalidone should check their bottle’s National Drug Code and batch number against the recalled lot. Anyone holding the affected RISA24002 batch should contact their pharmacist for a replacement rather than discard or stop taking the medication outright. For a drug this widely prescribed, the most responsible move is simple: verify the bottle, talk to a professional, and keep blood pressure under control while the supply chain sorts itself out.
Sources:
foxbusiness.com, api.fda.gov, boston25news.com, goodhousekeeping.com, aarp.org
